Mazumdar-Shaw, Chairman & Managing Director of Biocon, recently stated that Biocon is developing a portfolio of 10 biosimilars, and will continue to invest 12-15% of its revenue in research and development. According to Ms. Mazumdar-Shaw, Biocon’s biosimilars span insulin, monoclonal antibodies, and other recombinant proteins for markets in India and abroad. For instance, Biocon and Mylan’s aBLA for a biosimilar to trastuzumab was accepted by the FDA earlier this year.
Stay tuned to the Big Molecule Watch blog.
The post Mazumdar-Shaw Comments On Biocon’s Biosimilar Pipeline appeared first on Goodwin Procter BioSimilars Blog.